Addressing Unmet Needs in the Localized Advanced Head and Neck Cancer Market

AstraZeneca (AZN) has commenced the global Phase 3 eVOLVE-HNSCC trial to evaluate volrustomig (MEDI5752), a bispecific antibody, in patients with localized advanced squamous cell carcinoma of the head and neck (LA-HNSCC). This trial will compare the efficacy of volrustomig plus observation to observation alone in patients who are ineligible for surgery and have completed concurrent chemoradiotherapy (cCRT) without disease progression. Localized advanced head and neck cancer has a recurrence rate of up to 50%, but there are no standard-of-care approved drugs for maintenance therapy after cCRT, creating a significant need for maintenance treatment options. AstraZeneca aims to establish a presence in this area with significant unmet medical needs and expand its oncology portfolio.

Differentiated Dual Immune Checkpoint Inhibition Mechanism of Bispecific Antibody

Volrustomig is a monovalent bispecific, humanized monoclonal antibody that simultaneously targets PD-1, which induces immune evasion in cancer cells, and CTLA-4, which inhibits immune cell activation. It is designed to overcome the limitations of existing single-target cancer therapies, which have not been able to completely block immune-suppressive signals in the tumor microenvironment, by blocking both checkpoints simultaneously. In particular, it induces and promotes the activation of tumor-infiltrating lymphocytes (TILs), leading to synergistic effects and reduced toxicity compared to single-antibody combination therapy. This innovative platform may be a key alternative for reactivating the immune system in head and neck cancer patients with suppressed immune responses.

Strategy to Overcome the Barriers of Past Single-Agent Clinical Trials

The localized advanced head and neck cancer area is a challenging market where several global pharmaceutical companies have attempted to introduce immune-oncology therapies but failed. For example, both the KEYNOTE-412 trial, which evaluated MSD's Keytruda (pembrolizumab), and the JAVELIN Head and Neck 100 trial, which evaluated Pfizer's Avelumab, added immune-oncology therapies to existing therapies but failed to demonstrate improved survival rates. AstraZeneca analyzed the failure factors of these previous studies and adopted a differentiated design that involves administering the bispecific antibody, which simultaneously inhibits PD-1 and CTLA-4, as a single maintenance therapy after the completion of cCRT. This strategy aims to increase the intensity of immune activation, which was insufficient in previous trials, to improve the chances of success.

Commercialization Roadmap and Market Outlook with a Target of 2030 for Clinical Completion

The global head and neck cancer therapeutics market is estimated at approximately $2 billion to $2.9 billion in 2025 and is expected to grow rapidly at a compound annual growth rate (CAGR) of 7.5% to exceed $6 billion in 2035. The eVOLVE-HNSCC Phase 3 trial began enrolling patients in December 2023 and is actively recruiting patients, with a primary completion target of April 2030. If AstraZeneca obtains significant survival data in this trial, it will reshape the paradigm of head and neck cancer treatment from standard treatment followed by observation to an immune therapy-centered approach. This will drive the acquisition of a dominant market position and change the landscape of existing immune checkpoint inhibitors held by competitors.